Stockwatch: Awaking from bad dreams and nightmares
This article was originally published in Scrip
The 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) wound down in Chicago this week and coincided with Gilead Sciences’ announcement of a second positive phase III clinical trial for its 'Quad' once daily treatment for HIV infection (scripintelligence.com, 21 September 2011). The two events are closely linked and the history between them should give investors in Gilead significant hope for the continued dominance of Gilead's anti-HIV franchise in the developed world. Reassuringly for believers in the rationality of the stock market, the assessment of Gilead's prospects by investors have been firmly based on the fundamental measures, namely the performance of its anti-HIV drugs and drug combinations relative to those of its rivals.
You may also be interested in...
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.
The prices of biotechnology and pharmaceutical sector indices continue to be comparatively robust in the face of big falls in global markets as investors expect new drugs and vaccines to be generated by the sector. While it is largely accepted that the life science sector will eventually ride to the rescue, bumper profits are far from guaranteed.
Pharmaceutical shares are stronger than most as world stock markets dive downwards, but they are not immune to the coronavirus fallout. The effects will be felt by biopharma companies across many areas of their activity.